Showing results (341-350 of 385) with videos related to

Sort By:
Pageof 39
European Journal of Neurology|November 4, 2021
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosisRoberto Bergamaschi, Marta Ponzano, Irene Schiavetti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 19, 2020
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti, et al.
Nature Reviews. Neurology|January 15, 2025
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMTPaolo A Muraro, Alice Mariottini, Raffaella Greco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 7, 2015
The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania regionChiara de Waure, Francesco Di Nardo, Walter Mazzucco, et al.
Neurology and Therapy|June 2, 2022
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up StudyMaria Petracca, Serena Ruggieri, Elena Barbuti, et al.
Annals of Clinical and Translational Neurology|July 6, 2024
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Annals of Clinical and Translational Neurology|July 7, 2025
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple SclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Cell Reports|November 13, 2025
Noradrenergic control of bone marrow and thymus by AgRP neurons is impaired in experimental multiple sclerosisTiziana Vigo, Maria C Mariani, Caterina Bason, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 12, 2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison StudyAurora Zanghì, Antonio Gallo, Carlo Avolio, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 27, 2024
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experienceSerena Ruggieri, Antonio Ianniello, Massimiliano Copetti, et al.
Pageof 39